474 related articles for article (PubMed ID: 27565788)
1. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
[TBL] [Abstract][Full Text] [Related]
2. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
[TBL] [Abstract][Full Text] [Related]
3. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
4. Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients.
Sherani F; Boston C; Mba N
Curr Oncol Rep; 2019 Aug; 21(10):89. PubMed ID: 31418119
[TBL] [Abstract][Full Text] [Related]
5. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
Herrstedt J; Roila F; Warr D; Celio L; Navari RM; Hesketh PJ; Chan A; Aapro MS
Support Care Cancer; 2017 Jan; 25(1):277-288. PubMed ID: 27443154
[TBL] [Abstract][Full Text] [Related]
6. 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Roila F; Warr D; Hesketh PJ; Gralla R; Herrstedt J; Jordan K; Aapro M; Ballatori E; Rapoport B
Support Care Cancer; 2017 Jan; 25(1):289-294. PubMed ID: 27510316
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
8. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
10. 2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy.
Dupuis LL; Roscoe JA; Olver I; Aapro M; Molassiotis A
Support Care Cancer; 2017 Jan; 25(1):317-321. PubMed ID: 27510314
[TBL] [Abstract][Full Text] [Related]
11. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
[TBL] [Abstract][Full Text] [Related]
12. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials.
van der Vorst MJ; Neefjes EC; Konings IR; Verheul HM
Support Care Cancer; 2015 Aug; 23(8):2499-506. PubMed ID: 26041480
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
15. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.
Phillips RS; Friend AJ; Gibson F; Houghton E; Gopaul S; Craig JV; Pizer B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD007786. PubMed ID: 26836199
[TBL] [Abstract][Full Text] [Related]
17. Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis.
Patel P; Paw Cho Sing E; Dupuis LL
Expert Opin Drug Saf; 2019 Feb; 18(2):97-110. PubMed ID: 30640557
[TBL] [Abstract][Full Text] [Related]
18. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Rapoport BL
Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]